Actelion study leader says Opsumit missed PAH study endpoint

ZURICH (Reuters) - Actelion's Opsumit drug missed a primary endpoint in a study of patients with pulmonary arterial hypertension due to Eisenmenger Syndrome, a doctor involved in leading the trial said in a statement issued by the Swiss drugmaker on Monday.